A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Participants must meet all of the following criteria to be included in this study:

• Male or female, age 2 years and older at the time of informed consent
• Diagnosis of epilepsy with Dravet syndrome
• Has at least 4 convulsive seizures during the 4 weeks of baseline
• Current treatment with antiepileptic drugs must be stable for at least 4 weeks before screening, and be expected to remain stable throughout the study

Participants who meet any of the following criteria will be excluded from this study:

• Use of lorcaserin within 4 weeks before screening, or any history of it being discontinued due to lack of efficacy or adverse reactions
• Use of fenfluramine within 2 months before screening, any history of lack of fenfluramine efficacy, or any history of valvulopathy at baseline with history of fenfluramine use
• Recent or concomitant use of serotonergic medications or monoamine oxidase inhibitors
• Presence of progressive central nervous system disease other than Dravet syndrome